CN103772359B - 一种兰索拉唑化合物 - Google Patents
一种兰索拉唑化合物 Download PDFInfo
- Publication number
- CN103772359B CN103772359B CN201410038660.9A CN201410038660A CN103772359B CN 103772359 B CN103772359 B CN 103772359B CN 201410038660 A CN201410038660 A CN 201410038660A CN 103772359 B CN103772359 B CN 103772359B
- Authority
- CN
- China
- Prior art keywords
- lansoprazole
- crystal
- enteric coated
- crystal formation
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 title claims abstract description 54
- 229960003174 lansoprazole Drugs 0.000 title claims abstract description 54
- 150000001875 compounds Chemical class 0.000 title claims abstract description 11
- 239000013078 crystal Substances 0.000 claims abstract description 54
- 238000002360 preparation method Methods 0.000 claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 239000002662 enteric coated tablet Substances 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims abstract 3
- 239000002775 capsule Substances 0.000 claims abstract 2
- 239000007931 coated granule Substances 0.000 claims abstract 2
- 230000015572 biosynthetic process Effects 0.000 claims description 36
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 9
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims description 7
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 238000000967 suction filtration Methods 0.000 claims description 4
- 238000001291 vacuum drying Methods 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 11
- 239000011248 coating agent Substances 0.000 description 10
- 238000000576 coating method Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000012055 enteric layer Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- 230000027119 gastric acid secretion Effects 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000001711 oxyntic cell Anatomy 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229940126409 proton pump inhibitor Drugs 0.000 description 2
- 239000000612 proton pump inhibitor Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 102000003710 Histamine H2 Receptors Human genes 0.000 description 1
- 108090000050 Histamine H2 Receptors Proteins 0.000 description 1
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 description 1
- 108010083204 Proton Pumps Proteins 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- 230000004656 cell transport Effects 0.000 description 1
- 230000003153 cholinolytic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 208000000689 peptic esophagitis Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000011122 softwood Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410038660.9A CN103772359B (zh) | 2014-01-27 | 2014-01-27 | 一种兰索拉唑化合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410038660.9A CN103772359B (zh) | 2014-01-27 | 2014-01-27 | 一种兰索拉唑化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103772359A CN103772359A (zh) | 2014-05-07 |
CN103772359B true CN103772359B (zh) | 2015-09-30 |
Family
ID=50565177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410038660.9A Active CN103772359B (zh) | 2014-01-27 | 2014-01-27 | 一种兰索拉唑化合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103772359B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107011328B (zh) * | 2017-05-05 | 2019-10-15 | 广州大光制药有限公司 | 一种兰索拉唑化合物的晶型及其结晶制备方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101514199B (zh) * | 2009-03-31 | 2012-06-20 | 张锡芬 | 一种兰索拉唑化合物及其制法 |
CN102108077B (zh) * | 2009-12-23 | 2013-09-25 | 江苏豪森医药集团有限公司 | 制备右兰索拉唑的方法 |
CN102399212B (zh) * | 2010-08-23 | 2014-07-16 | 江苏豪森医药集团有限公司 | 一种右兰索拉唑晶型及其制备方法 |
-
2014
- 2014-01-27 CN CN201410038660.9A patent/CN103772359B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN103772359A (zh) | 2014-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2010215269B2 (en) | Tosylate salt of a 5-pyrazolyl-2-pyridone derivative, useful in the treatment of COPD | |
TWI659028B (zh) | 苯并咪唑衍生物((S)-4-(5,7-二氟唍-4-基氧基)-N,N,2-三甲基-1H-苯并[d]咪唑-6-甲醯胺)之酸加成鹽 | |
TW200838512A (en) | Crystalline forms of a thiazolidinedione compound and manufacturing methods thereof | |
RU2613555C2 (ru) | Моногидратный кристалл калиевой соли фимасартана, способ его получения и содержащая его фармакологическая композиция | |
KR101841662B1 (ko) | 프로톤 펌프 저해제의 고체분산체 및 이를 포함하는 약제학적 조성물 | |
WO2021227146A1 (zh) | N-[8-(2-羟基苯甲酰基)氨基]辛酸一钾晶型化合物、制备方法及用途 | |
EP3229791A2 (en) | Novel polymorphs of ivacaftor, process for its preparation and pharmaceutical composition thereof | |
CN102140099A (zh) | 新的吡啶衍生物 | |
CN103772359B (zh) | 一种兰索拉唑化合物 | |
WO2015003571A1 (zh) | 达拉菲尼甲磺酸盐的新晶型及其制备方法 | |
CN103509001B (zh) | 一种埃索美拉唑镁三水合物及其制备方法 | |
CN104072482A (zh) | 一种雷贝拉唑钠化合物及其药物组合物 | |
EP3811941B1 (en) | Pharmaceutical composition containing ilaprazole and salt thereof and preparation method therefor | |
CN110452233B (zh) | 一种奥美沙坦酯的晶型及其制备方法 | |
CN108863765B (zh) | 一种洛索洛芬钠结晶的制备方法 | |
CN107311984B (zh) | 一种右旋艾普拉唑钠化合物及其药物组合物和制备方法 | |
CN105566294A (zh) | 一种右旋艾普拉唑钠化合物及其药物组合物 | |
JPWO2006132217A1 (ja) | ベンズイミダゾール化合物の塩の結晶 | |
CN104031032B (zh) | 一种埃索美拉唑钠化合物及其药物组合物 | |
CN105218522B (zh) | 一种右旋艾普拉唑化合物及其药物组合物 | |
US20170197937A1 (en) | New crystal form of pantoprazole sodium compound and preparation method therefor | |
CN101492452B (zh) | 含有二氧杂环庚烷并吡啶的巯基苯并咪唑衍生物 | |
CN105055411A (zh) | 一种治疗胃溃疡的药物泮托拉唑钠组合物 | |
CN113045544A (zh) | 艾普拉唑钠化合物及其药物组合物 | |
CN101497605B (zh) | 含有被烷氧基取代的吡啶的苯并咪唑衍生物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20151201 Address after: 611130, Chengdu District, Sichuan, Wenjiang province Chengdu science and Technology Industrial Development Park on both sides of the Taiwan Straits, No. 433 west section of Willow Road Patentee after: CHENGDU BAIYU TECHNOLOGY PHARMACY Co.,Ltd. Address before: 710016, No. 1, building 1, building 48, Tai Hing East Road, Lianhu District, Lianhu District, Shaanxi, Xi'an, 13 Patentee before: Ma Kui Patentee before: Hong Jun |
|
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 611130, Chengdu District, Sichuan, Wenjiang province Chengdu science and Technology Industrial Development Park on both sides of the Taiwan Straits, No. 433 west section of Willow Road Patentee after: CHENGDU BAIYU PHARMACEUTICAL Co.,Ltd. Address before: 611130, Chengdu District, Sichuan, Wenjiang province Chengdu science and Technology Industrial Development Park on both sides of the Taiwan Straits, No. 433 west section of Willow Road Patentee before: CHENGDU BAIYU TECHNOLOGY PHARMACY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231022 Address after: No. 343 Hezuo Road, Chengdu High tech Zone, Chengdu, Sichuan Province, 611730 Patentee after: Sichuan Hongming Bosi Pharmaceutical Co.,Ltd. Address before: 611130 No. 433, west section of Liutai Avenue, Chengdu cross strait science and Technology Industrial Development Park, Wenjiang District, Chengdu City, Sichuan Province Patentee before: CHENGDU BAIYU PHARMACEUTICAL Co.,Ltd. |